Running a full marathon isn’t a piece of cake for trained athletes, let alone people who struggle to breathe under normal circumstances. Yet two Spaniards with cystic fibrosis (CF) will be among the 40,000 people running in Madrid’s Rock ‘n’ Roll Marathon on Sunday, April 23. The annual 42-kilometer race, which…
News
The United States and Canada have given Laurent Pharmaceuticals a green light for a Phase 2 clinical trial of LAU-7b as a treatment for cystic fibrosis (CF) in adults. The Phase 2 door was opened when the U.S. Food and Drug Administration (FDA) and Health Canada approved the company’s investigational new drug (IND) application…
The first of a series of young-adult fantasy books from Michael Seidelman features a teenage girl with cystic fibrosis (CF). “No One Dies in the Garden of Syn,” whose main character is Synthia “Syn” Wade, explores topics that let young readers know more about the disease. Seidelman will donate…
Researchers at the University of Missouri School of Medicine have developed a helium-based imaging technique to measure how well Kalydeco, which fights mucus build-up in the lungs, is able to help cystic fibrosis (CF) patients. They discovered that it dramatically improved patients’ respiratory function. Helium imaging also can identify…
Arch Biopartners is on the verge of its first clinical trial of AB569, an inhalation treatment for antibiotic-resistant bacteria that infect the lungs of those with cystic fibrosis (CF) and other pulmonary conditions. The Phase 1 clinical trial, to be conducted at the Cincinnati Veterans Affairs Medical Center (CVAMC),…
Novoclem Therapeutics’ lead drug candidate, a nitric oxide-releasing biopolymer, can eliminate nine of the most prevalent microorganisms responsible for severe lung infections in cystic fibrosis (CF) patients, the Morrisville, N.C., company reported. “Our mission is to arm patients with therapies that treat resistant bacteria and enable them to breathe…
A small proof-of-concept Phase 2 trial (NCT02722122) of alidornase alfa showed that the therapy improved lung function in patients with cystic fibrosis (CF), according to its developer Protalix BioTherapeutics. In addition to making breathing difficult, the thick mucus in CF patients’ airways makes ideal growth conditions for many…
Swiss-based Polyphor has secured financing for late-stage development of Murepavadin (POL7080), an antibiotic targeting a bacteria that often infects the airways of cystic fibrosis (CF) patients. A hallmark of the therapy is that it goes after antibiotic-resistant strains of Pseudomonas aeruginosa, which infects not just MS patients, but people with other…
A pancreatic enzyme replacement product that is not derived from pigs — Sollpura (liprotamase) — was as good at maintaining the height and weight of cystic fibrosis (CF) patients as a pig-derived product, according to a clinical trial. The information came from the extension period of Anthera’s Phase 3…
The naturally occurring molecule thymosin α1 (Tα1) reversed tissue defects in mice with cystic fibrosis (CF) and in human cells that contained a mutation associated with the disease, according to a study. The findings mean that Tα1 could be a promising treatment for CF patients carrying the F508del mutation in…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.